The implications of high prices for cancer drugs on health care costs and patients' financial burdens are a growing concern. Patients with metastatic castrate-resistant prostate cancer (mCRPC) are ...
An interview with Dr. Katherine S. Virgo from Emory University in Atlanta, GA on “Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer: ASCO Guideline Update.” This ...
An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer. This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of ...
According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results